STA Pharmaceutical has reported rapid growth in companies intending to market their products in China using it as a partner following the Chinese Food and Drug Administration’s (CFDA) announcement of the Market Authorization Holder (MAH) pilot programme last year.
China flag
The MAH pilot programme was launched to allow drug licence holders the use of qualified contract manufacturing service providers in certain geographic areas (10 trial provinces and municipalities), with the aim of increasing innovation as biotech companies would no longer be required to invest in their own manufacturing facilities.